|D016393||Lymphoma, B-Cell NIH||1.00|
There is one clinical trial.
This study is being done to see if the investigational drug, anakinra, prevent or reverse the severe side effects caused by CAR-T cell therapy.
Description: Determine the rate of severe neurotoxicities, >/= Grade 3 or any grade seizure, within the first 4 weeks of treatment with prophylactic use of anakinra in participants receiving CD19-specific CAR T cellsMeasure: Arm 1 (CAR T Cell Group) Rate of Severe Neurotoxicities Time: 4 weeks
Description: proportion of patients able to avoid death or mechanical ventilation within 28 days from the start of the treatment.Measure: Arm 2 (COVID-19 Group) proportion of patients able to avoid death or mechanical ventilation Time: 28 days from the start of treatment
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports